Market revenue in 2023 | USD 450.3 million |
Market revenue in 2030 | USD 647.8 million |
Growth rate | 5.3% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 59.92% in 2023. Horizon Databook has segmented the Italy inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The Italy inflammatory bowel disease treatment market is primarily driven by an increasing number of patients with IBD in the country. In 2020, the estimated number of IBD cases in the country was 451,875 and is expected to increase to 591,960 by 2030.
Moreover, according to an article published by Frontiers Media S.A., edited by a professor from the University of Milan, the increasing prevalence of IBD in the country and new product developments are likely to be major factors driving the market in Italy.
In addition, R&D on novel products, such as oligonucleotides, in different Italian universities is expected to contribute to the market growth. Moreover, growing development and commercialization of biosimilars in the country are expected to boost market growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Italy inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account